A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2020-10-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics
(PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with
atopic dermatitis (AD).